Literature DB >> 14716817

Expression of NF-kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions.

Wei Wang1, He-Sheng Luo, Bao-Ping Yu.   

Abstract

AIM: To investigate the expression of NF-kappaBp65 protein and human telomerase reverse transcriptase (hTERT) and their correlation in gastric cancer and precancerous lesions.
METHODS: Forty-one patients with primary gastric cancer, 15 with dysplasia, 23 intestinal metaplasia and 10 with normal gastric mucosa were included in this study. Expression of NF-kappaBp65 protein, hTERT mRNA and protein were determined by immunohistochemistry and in situ hybridization.
RESULTS: The rate of p65 expression in normal gastric mucosa, intestinal metaplasia, dysplasia and carcinoma was 0%, 34.78%, 53.33% and 60.98%, respectively, while the rate of hTERT mRNA expression was 10.00%, 39.13%, 66.67% and 85.37% and the rate of hTERT protein expression was 0%, 30.43%, 60.00% and 78.05%, respectively. All the three parameters were significantly increased in dysplasia and carcinoma compared to normal mucosa, while the expression levels were also significantly higher in carcinoma than in intestinal metaplasia (P<0.05). In gastric cancer tissues, nuclear staining rates of p65 and hTERT protein were both significantly associated with the degree of differentiation, lymph node metastasis, clinical stage and invasion depth (P<0.05). However, hTERT mRNA expression was only significantly associated with clinical stage. There was a positive correlation between p65 and hTERT mRNA (rs=0.661-0.752, P<0.01), and between hTERT protein and hTERT mRNA (rs=0.609-0.750, P<0.01).
CONCLUSION: NF-kappaBp65 and hTERT expressions are upregulated at the early stage of gastric carcinogenesis. NF-kappaB activation may contribute to hTERT expression and thereby enhance telomerase activity, which represents an important step in carcinogenesis progress.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716817      PMCID: PMC4716998          DOI: 10.3748/wjg.v10.i2.177

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

Review 1.  Telomerases.

Authors:  E H Blackburn
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

2.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.

Authors:  N Sasaki; T Morisaki; K Hashizume; T Yao; M Tsuneyoshi; H Noshiro; K Nakamura; T Yamanaka; A Uchiyama; M Tanaka; M Katano
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

4.  Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas.

Authors:  J Nakayama; H Tahara; E Tahara; M Saito; K Ito; H Nakamura; T Nakanishi; E Tahara; T Ide; F Ishikawa
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

5.  Effect of cholecystokinin octapeptide on tumor necrosis factor alpha transcription and nuclear factor-kappaB activity induced by lipopolysaccharide in rat pulmonary interstitial macrophages.

Authors:  Bin Cong; Shu-Jin Li; Yu-Xia Yao; Gui-Jun Zhu; Yi-Ling Ling
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

6.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

7.  Mutation analysis of novel human liver-related putative tumor suppressor gene in hepatocellular carcinoma.

Authors:  Cheng Liao; Mu-Jun Zhao; Jing Zhao; Hai Song; Pascal Pineau; Agnes Marchio; Anne Dejean; Pierre Tiollais; Hong-Yang Wang; Tsai-Ping Li
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

8.  The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors.

Authors:  H Akari; S Bour; S Kao; A Adachi; K Strebel
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

9.  Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy.

Authors:  A M Burger; M C Bibby; J A Double
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas.

Authors:  W Yasui; H Tahara; E Tahara; J Fujimoto; J Nakayama; F Ishikawa; T Ide; E Tahara
Journal:  Jpn J Cancer Res       Date:  1998-11
View more
  20 in total

1.  hTERT and TP53 deregulation in intestinal-type gastric carcinogenesis in non-human primates.

Authors:  Mariana Ferreira Leal; Danielle Queiroz Calcagno; André Salim Khayat; Tanielly Cristina Raiol Silva; José Augusto Pereira Carneiro Muniz; Paulo Pimentel Assumpção; Marília de Arruda Cardoso Smith; Rommel Rodríguez Burbano
Journal:  Clin Exp Med       Date:  2012-06-17       Impact factor: 3.984

Review 2.  RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.

Authors:  Gowri Palanissami; Solomon F D Paul
Journal:  Horm Cancer       Date:  2018-07-09       Impact factor: 3.869

3.  Tumor metastasis and the reciprocal regulation of heparanase gene expression by nuclear factor kappa B in human gastric carcinoma tissue.

Authors:  Hou-Jun Cao; Yong Fang; Xing Zhang; Wen-Jun Chen; Wen-Peng Zhou; Hong Wang; Lin-Bo Wang; Jin-Min Wu
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

4.  Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer.

Authors:  Yi Kang; Jiancheng Zhang; Peichun Sun; Jia Shang
Journal:  Int J Clin Oncol       Date:  2012-04-12       Impact factor: 3.402

5.  IkappaBalpha polymorphism at promoter region (rs2233408) influences the susceptibility of gastric cancer in Chinese.

Authors:  Shiyan Wang; Linwei Tian; Zhirong Zeng; Mingdong Zhang; Kaichun Wu; Minhu Chen; Daiming Fan; Pinjin Hu; Joseph J Y Sung; Jun Yu
Journal:  BMC Gastroenterol       Date:  2010-02-05       Impact factor: 3.067

6.  Prognostic role of telomerase activity in gastric adenocarcinoma: A meta-analysis.

Authors:  Mu-Han Lü; Jia-Qi Deng; Ya-Ling Cao; Dian-Chun Fang; Yao Zhang; Shi-Ming Yang
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

7.  Telomerase and hTERT: can they serve as markers for gastric cancer diagnosis?

Authors:  Yong-Bo Cheng; Li-Ping Guo; Ping Yao; Xiao-Yan Ning; Gulimire Aerken; Dian-Chun Fang
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

8.  A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.

Authors:  R C Turkington; C Purcell; C R James; J Millar; E Napier; D Law; R Gallagher; M Morris; R H Wilson; M M Eatock
Journal:  Invest New Drugs       Date:  2013-05-11       Impact factor: 3.850

9.  Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaB a and prognostic significance.

Authors:  Georgia Levidou; Penelope Korkolopoulou; Nikolaos Nikiteas; Nikolaos Tzanakis; Irene Thymara; Angelica A Saetta; Christos Tsigris; George Rallis; Konstantin Vlasis; Efstratios Patsouris
Journal:  Virchows Arch       Date:  2007-04-12       Impact factor: 4.064

10.  Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma.

Authors:  Ahmed S Abdulamir; Rand R Hafidh; Layla K Mahdi; Tarik Al-jeboori; Fatimah Abubaker
Journal:  BMC Cancer       Date:  2009-11-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.